Note: Use only under medical supervision
Results from the improvement in liver scarring endpoint trended to favor semaglutide 2.4 mg across weight thresholds when compared to placebo, with an improvement in liver scarring observed in 27.2% of patients receiving semaglutide 2.4 mg versus in 18.3% of those receiving placebo within the 2% subgroup (EDP * 8.3, 95% CI -6.1, 22.9)
During the Covid era no live partner dancing for me
Garolla A, Maiorino M, Roverato A, Roveri A, Ursini F, Foresta C
The doctors took time to understand my concerns without rushing or pressuring me into any procedure
My dietitian, Kristen, and I, Ive been meeting for over two months or so, and I truly appreciate the guidance and concern concerns that she shares with me throughout the visit